Aberdeen Group plc Has $5.98 Million Stake in Personalis, Inc. $PSNL

Key Points

• Aberdeen Group plc increased its stake in Personalis, Inc. by 472.3%, acquiring an additional 1,406,895 shares, leading to ownership of 1.93% of the company worth approximately $5.98 million.
• Other institutional investors, including JPMorgan Chase & Co. and Barclays PLC, have significantly increased their holdings in Personalis during the fourth quarter.
• Personalis reported a quarterly EPS of ($0.23), surpassing the expected loss of ($0.25), although revenue fell short of projections at $17.20 million.

Aberdeen Group plc raised its stake in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 472.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,704,784 shares of the company's stock after purchasing an additional 1,406,895 shares during the period. Aberdeen Group plc owned approximately 1.93% of Personalis worth $5,984,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Personalis in the 4th quarter valued at $28,000. JPMorgan Chase & Co. lifted its holdings in shares of Personalis by 2,827.0% during the 4th quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock worth $34,000 after acquiring an additional 5,654 shares during the period. Alpine Global Management LLC bought a new position in shares of Personalis during the 4th quarter worth about $60,000. Raymond James Financial Inc. bought a new position in shares of Personalis during the 4th quarter worth about $64,000. Finally, Boothbay Fund Management LLC bought a new position in shares of Personalis during the 4th quarter worth about $73,000. 61.91% of the stock is owned by institutional investors.

Personalis Trading Up 3.8%

Shares of Personalis stock traded up $0.18 during mid-day trading on Tuesday, reaching $4.88. 742,397 shares of the stock were exchanged, compared to its average volume of 1,122,636. The company has a market cap of $432.76 million, a price-to-earnings ratio of -3.81 and a beta of 1.86. The firm has a 50-day simple moving average of $5.88 and a 200 day simple moving average of $4.85. Personalis, Inc. has a fifty-two week low of $2.83 and a fifty-two week high of $7.79.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. The firm had revenue of $17.20 million during the quarter, compared to analysts' expectations of $20.12 million. Personalis had a negative net margin of 113.70% and a negative return on equity of 47.57%. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, research analysts predict that Personalis, Inc. will post -1.4 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Guggenheim assumed coverage on shares of Personalis in a report on Thursday, May 15th. They set a "buy" rating and a $6.00 price objective for the company. BTIG Research set a $6.00 price objective on shares of Personalis in a report on Wednesday, August 6th. Wall Street Zen downgraded shares of Personalis from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Finally, HC Wainwright reduced their price objective on shares of Personalis from $9.00 to $8.50 and set a "buy" rating for the company in a report on Wednesday, August 6th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $7.42.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.